Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.
Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback